Sun Pharma’s acquisition of US-based Organon looks like a financial bargain for the global scale and market access it offers. But the Indian drugmaker may need to look elsewhere for an R&D boost that could put it at the cutting edge of healthcare. For the full story, visit the source.
Business
Sun Pharma’s deal to buy Merck-spinoff Organon ticks the right box on acquisition cost if not R&D
Sun Pharma’s acquisition of US-based Organon looks like a financial bargain for the global scale and market access it offers. But the Indian drugmaker may need to look elsewhere for an R&D boost that could put it at the cutting edge of healthcare.
By Mint Editorial Board· Livemint· 1 month ago· 2 min read
This summary is sourced from Livemint. Read the full article at:Livemint